FR2380782A1 - Fraction 5 de thymosine stabilisee utile comme medicament et procede pour la preparer - Google Patents

Fraction 5 de thymosine stabilisee utile comme medicament et procede pour la preparer

Info

Publication number
FR2380782A1
FR2380782A1 FR7804718A FR7804718A FR2380782A1 FR 2380782 A1 FR2380782 A1 FR 2380782A1 FR 7804718 A FR7804718 A FR 7804718A FR 7804718 A FR7804718 A FR 7804718A FR 2380782 A1 FR2380782 A1 FR 2380782A1
Authority
FR
France
Prior art keywords
thymosin
fraction
useful
stabilized
preparing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
FR7804718A
Other languages
English (en)
Other versions
FR2380782B1 (fr
Inventor
Weldon Courtney Mcgregor
Harold Leon Newmark
Armin Hermann Ramel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of FR2380782A1 publication Critical patent/FR2380782A1/fr
Application granted granted Critical
Publication of FR2380782B1 publication Critical patent/FR2380782B1/fr
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2292—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne une forme solide stable de fraction 5 de thymosine exempte d'endotoxines et de pyrogènes. Cette forme de fraction 5 de thymosine est préparée par un procédé comprenant en combinaison : a. L'ultrafiltration d'une solution aqueuse de fraction 5 de thymosine tamponnée avec un tampon basique faiblement volatil à un pH de 7 à 8 à travers une membrane ayant un seuil de coupure correspondant à une masse moléculaire de 10 000 environ; b. L'addition d'un agent antimicrobien de type phénolique au produit de perméation et d'un agent de tamponnage en quantité suffisante pour fournir un pH de 7-8 lors de la reconstitution, et c. La lyophilisation du produit de perméation, l'agent antimicrobien du type phénolique étant retenu avec la fraction 5 de thymosine lyophilisée. Cette forme stable est utile à la préparation de solution pour injection.
FR7804718A 1977-02-22 1978-02-20 Fraction 5 de thymosine stabilisee utile comme medicament et procede pour la preparer Granted FR2380782A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US05/770,480 US4082737A (en) 1977-02-22 1977-02-22 Stabilized thymosin composition and method

Publications (2)

Publication Number Publication Date
FR2380782A1 true FR2380782A1 (fr) 1978-09-15
FR2380782B1 FR2380782B1 (fr) 1980-01-18

Family

ID=25088687

Family Applications (1)

Application Number Title Priority Date Filing Date
FR7804718A Granted FR2380782A1 (fr) 1977-02-22 1978-02-20 Fraction 5 de thymosine stabilisee utile comme medicament et procede pour la preparer

Country Status (20)

Country Link
US (1) US4082737A (fr)
JP (1) JPS53104719A (fr)
AT (1) AT363177B (fr)
AU (1) AU516946B2 (fr)
BE (1) BE864139A (fr)
CA (1) CA1099633A (fr)
CH (1) CH632164A5 (fr)
DE (1) DE2807202C2 (fr)
DK (1) DK78378A (fr)
FR (1) FR2380782A1 (fr)
GB (1) GB1546027A (fr)
IE (1) IE46409B1 (fr)
IL (1) IL54063A0 (fr)
IT (1) IT1092337B (fr)
LU (1) LU79090A1 (fr)
NL (1) NL189281C (fr)
NZ (1) NZ186489A (fr)
PH (1) PH13858A (fr)
SE (1) SE444647B (fr)
ZA (1) ZA78890B (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2732587A1 (de) * 1976-09-22 1978-03-23 Bach Jean Francois Polypeptid mit thymischer wirksamkeit
US4148788A (en) * 1978-01-23 1979-04-10 Hoffmann-La Roche Inc. Synthesis of thymosin α1
US4239498A (en) * 1978-11-27 1980-12-16 Rule Allyn H Method of preparing thymic factors and composition
US4264571A (en) * 1979-01-22 1981-04-28 George Washington University Radioimmunoassay of thymosin α1
EP0057702A1 (fr) * 1980-08-08 1982-08-18 Rak-A-Van Pty Limited Systeme d'etageres ameliore
US4389343A (en) * 1981-12-24 1983-06-21 Hoffmann-La Roche Inc. Immunopotentiating peptides from thymus
US4388234A (en) * 1981-12-28 1983-06-14 Hoffmann-La Roche Inc. Peptide isolation
US4614731A (en) * 1983-09-15 1986-09-30 Hoffmann-La Roche Inc. Peptide having immunopotentiating activity similar to thymosin alpha1
US4659694A (en) * 1983-10-27 1987-04-21 Hoffmann-La Roche Inc. Prothymosin alpha
US4814434A (en) * 1984-02-03 1989-03-21 Ventres Laboratories, Inc. Inducer of T-suppressor cells
DE3633651A1 (de) * 1986-10-03 1988-04-14 Alfred Dr Dick Verwendung von fraktionen aus thymus- und milzextrakten zur behandlung der psoriasis
US5273963A (en) * 1991-03-29 1993-12-28 The George Washington University Compositions and methods for treating small cell and nonsmall cell lung cancers
JP4404866B2 (ja) 2006-03-03 2010-01-27 ゼライス株式会社 エンドトキシン含有量を低減したゼラチンの製造方法および低エンドトキシンゼラチン

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4002602A (en) * 1974-03-11 1977-01-11 Gideon Goldstein Ubiquitous immunopoietic polypeptide (UBIP) and methods
US4010148A (en) * 1975-05-12 1977-03-01 Board Of Regents Of The University Of Texas System Purified thymosin and process
US4002740A (en) * 1975-08-21 1977-01-11 Gideon Goldstein Tridecapeptide compositions and methods

Also Published As

Publication number Publication date
JPS618806B2 (fr) 1986-03-18
IE780335L (en) 1978-08-22
CH632164A5 (de) 1982-09-30
SE7802014L (sv) 1978-08-23
NL189281C (nl) 1993-03-01
AU3334378A (en) 1979-08-23
IT1092337B (it) 1985-07-06
FR2380782B1 (fr) 1980-01-18
AT363177B (de) 1981-07-10
JPS53104719A (en) 1978-09-12
AU516946B2 (en) 1981-07-02
BE864139A (fr) 1978-08-21
DE2807202C2 (de) 1987-04-02
NL189281B (nl) 1992-10-01
DE2807202A1 (de) 1978-08-24
IT7819791A0 (it) 1978-01-30
ZA78890B (en) 1979-01-31
SE444647B (sv) 1986-04-28
GB1546027A (en) 1979-05-16
PH13858A (en) 1980-10-22
IL54063A0 (en) 1978-04-30
LU79090A1 (fr) 1979-05-25
US4082737A (en) 1978-04-04
ATA124578A (de) 1980-12-15
NL7801422A (nl) 1978-08-24
CA1099633A (fr) 1981-04-21
NZ186489A (en) 1981-01-23
DK78378A (da) 1978-08-23
IE46409B1 (en) 1983-06-01

Similar Documents

Publication Publication Date Title
FR2380782A1 (fr) Fraction 5 de thymosine stabilisee utile comme medicament et procede pour la preparer
ATE271863T1 (de) Schilddrüsenhormone enthaltende stabilisierte arzneimittel und verfahren
ES2113346T3 (es) Metodo para potenciar el transporte de moleculas exogenas a traves de la membrana.
KR950016783A (ko) 조절 방출용 약학 조성물
SE8300623D0 (sv) Farmaceutisk komposition innehallande stabil mikrokristallin cis-platina(ii)-diammindiklorid (cisplatin)
GR3000534T3 (en) Aqueous alcaline injectable solution of torasemid ready for use and process for preparation thereof
EA199600024A2 (ru) Жидкая стабильная фармацевтическая композиция, содержащая уратоксидазу и лиофилизат для ее получения
NO870560L (no) Nytt farmasoeytisk preparat.
EP0173664A3 (fr) Dérivés de benzimidazole biologiquement actifs et leur procédé de préparation
HU907653D0 (en) Process for the preparation of a medical product with cyclosporine content for oral use
EA000211B1 (ru) Фармацевтические композиции для парентерального применения, содержащие индолкарбоновые кислоты
GB1514049A (en) Cross-linked orgotein
TR199800716T2 (xx) Trombosit k�melenme inhibit�rleri ihtiva eden farmas�tik terkipler.
US4822782A (en) Method for treating AIDS using streptovaricin C compounds
KR910015297A (ko) 오메프라졸 경구용 약제와 그 제조방법
JPS6045532A (ja) 血糖降下剤
SE8106498L (sv) Kvaternera salter av n,n3-di(beta-brompropionyl)-n1,n2-dispirotripiperazinium, forfarande for framstellning av desamma och lekemedelspreparat innehallande desamma
KR950000149A (ko) 오메프라졸 주사용 제제
KR880003623A (ko) 시알로실글리세로리피드로 된 신경장해질환 치료제
KR820000291B1 (ko) 불용성 약제의 가용화 방법
JPS6045527A (ja) 血圧降下剤
KR960041363A (ko) 우레이트 옥시디아제를 함유하는 안정한 액체 조성물 및 그의 제조를 위한 동결건조조성물
KR890001528A (ko) 성인 t-세포 백혈병/임파종의 억제를 위한 아바론, 아바롤 및 그 유도체의 용도
KR900000081A (ko) 트리암테렌의 약학적 액제

Legal Events

Date Code Title Description
TP Transmission of property
ST Notification of lapse